The Alliance for Biosecurity is supported by its member companies; the Center for Biosecurity is a member but neither contributes to nor receives funds from the Alliance.

The Alliance is a collaboration among the Center for Biosecurity and 13 pharmaceutical and biotechnology companies whose mission is to work in the public interest to improve prevention and treatment of severe infectious diseases—particularly those diseases that present global security challenges.

Members of the Alliance
Avecia
Bavarian Nordic
Center for Biosecurity of UPMC
Cangene Corporation
DOR BioPharma, Inc.
DynPort Vaccine Company LLC, a CSC company
Elusys Therapeutics, Inc.
Emergent BioSolutions
Hematech, Inc., a subsidiary of Kirin Pharma Company, Ltd.
Human Genome Sciences, Inc.
Iomai Vaccines
NanoViricides, Inc.
Pfizer Inc.
PharmAthene
Siga Technologies, Inc.

Associate Members
Battelle Medical Research and Evaluation Facility
Lovelace Respiratory Research Institute

The Threats 
The United States faces unprecedented risks to national security in the 21st century posed by the clear and growing danger of bioterrorism or a destabilizing infectious disease pandemic. Our nation’s vulnerability to biothreats is so severe simply because most of the vaccines and medicines that will be needed to protect our citizens during and after such events do not now exist, and will likely require several years and several hundred million dollars each to successfully develop and produce.

Alliance Mission
The Alliance for Biosecurity works to promote a stronger, more effective partnership between government and the BioPharma industry to better develop critically needed medical countermeasures. The Alliance also seeks to usher in a new era in the prevention and treatment of severe infectious diseases that present global security challenges. This new era will be characterized by the capacity to rapidly develop, produce, and stockpile medical countermeasures for the country. The Center for Biosecurity and BioPharma members of the Alliance are striving to create a long-term national security vision for achieving and sustaining defenses against a range of current and future biothreats.

Alliance Activities
Much can and should be done by public and private partners in advance of a bioterrorist attack or natural pandemic to minimize illness and death, as well as catastrophic social, economic, and political disruption. The Alliance pursues opportunities to partner with government and other stakeholders to develop new solutions aimed at greatly enhancing our country’s ability to defend itself against biothreats.

Sample Alliance activities include:

• Educating members of Congress and other government stakeholders about biosecurity and drug development issues.
• Promoting the creation and successful implementation of the Biodefense Advanced Research and Development Authority (BARDA) within DHHS.
• Submitting a manuscript for publication about the challenges of animal model development under the FDA’s Animal Efficacy Rule and presenting proposed solutions.
• Pursuing a public-private collaboration on animal model development issues.
• Providing venues for stakeholder dialogue about key biosecurity policy issues.
• Developing and presenting consensus policy proposals to government.